Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Janus Living Inc. Class A-1 Common Stock (JAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Janus Living Inc. Class A-1 Common Stock — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.79B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 4.6× Janus Living Inc. Class A-1 Common Stock's market cap, and Janus Living Inc. Class A-1 Common Stock pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| GEHC | JAN | |
|---|---|---|
Market Cap | $30.93B | $6.79B |
Volume | 5,033,451 | 1,802,875 |
Sector | Health | Real Estate |
52-Week High | $88.16 | $31.76 |
52-Week Low | $59.48 | $22.88 |
Enterprise Value | $39.39B | $6.88B |
Dividend Yield | 0.23% | 1.97% |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →
